Gland Pharma Limited has informed the Exchange about Investor Presentation
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma reported strong Q1FY26 results with consolidated revenue of ₹15,056 Mn, up 7% YoY. EBITDA grew 39% YoY to ₹3,678 Mn, with margin expanding sharply from 19% to 24%. PAT rose 50% YoY to ₹2,155 Mn, with margin improving from 10% to 14%. The base Gland business saw EBITDA margin expand from 29% to 35% YoY. The company launched 12 new molecules in regulated markets, filed 1 ANDA, and received 9 approvals (cumulative 372 filings, 325 approved). GLP-1/Pen/cartridge capacity is being scaled from ~40 million to 140 million units. Subsidiary Cenexi hit breakeven EBITDA versus losses a year ago. The US contributed 49% of group revenue, Europe 22%.
Strong margin expansion and 50% PAT growth signal improving profitability and operating leverage, likely positive for the stock. The GLP-1 capacity ramp-up and complex injectables pipeline are key future growth drivers for shareholders to watch.